Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces Leadership Team Promotions
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback